TELEFLEX INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206.7 USD | 0.00% |
|
+0.07% | -17.10% |
Financials (USD)
| Sales 2024 * | 3.09B | Sales 2025 * | 3.27B | Capitalization | 9.74B |
|---|---|---|---|---|---|
| Net income 2024 * | 365M | Net income 2025 * | 501M | EV / Sales 2024 * | 3.32 x |
| Net Debt 2024 * | 534M | Net cash position 2025 * | 34M | EV / Sales 2025 * | 2.97 x |
| P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
19.9
x | Employees | 14,500 |
| Yield 2024 * |
0.66% | Yield 2025 * |
0.67% | Free-Float | 97.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teleflex Incorporated
More recommendations
More press releases
More news
| 1 week | +0.07% | ||
| Current month | -8.60% | ||
| 1 month | -4.47% | ||
| 3 months | -15.44% | ||
| 6 months | +14.24% | ||
| Current year | -17.10% |
1 week
205.39
212.56
1 month
205.26227.65
Current year
205.26256.85
1 year
177.63276.43
3 years
177.63449.38
5 years
177.63449.38
10 years
99.56449.38
| Managers | Title | Age | Since |
|---|---|---|---|
Liam Kelly
CEO | Chief Executive Officer | 57 | 08-12-31 |
Thomas Powell
DFI | Director of Finance/CFO | 62 | 11-07-31 |
Howard Cyr
CMP | Compliance Officer | - | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Krakauer
BRD | Director/Board Member | 69 | 17-12-31 |
Stuart Randle
BRD | Director/Board Member | 64 | 08-12-31 |
John Heinmiller
BRD | Director/Board Member | 69 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.03% | 16 M€ | -8.49% | ||
| 0.73% | 8 M€ | +2.44% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 206.7 | 0.00% | 433,169 |
| 24-04-25 | 206.7 | -2.11% | 345,088 |
| 24-04-24 | 211.2 | +0.03% | 201,415 |
| 24-04-23 | 211.1 | +1.85% | 284,357 |
| 24-04-22 | 207.3 | +0.34% | 329,746 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
Teleflex Incorporated specialises in the designing, manufacturing and selling of single-use medical devices for hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Products are sold under the brand names Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck®. Net sales break down by category of products as follows:
- interventional cardiology, radiology and urology products (26.5%);
- vascular access solutions (25.9%);
- surgical devices (12.5%);
- anesthesia products (11.9%);
- other (23.2%).
Net sales are distributed geographically as follows: the United States (61.8%), Europe (25.5%), Asia-Pacific (9.1%) and other (3.6%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
206.7
USD
Average target price
262.4
USD
Spread / Average Target
+26.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.10% | 9.74B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- TFX Stock
